Biologics recommendations in the ECCO guidelines on therapeutics in Crohn's disease: medical treatment

Related Experiment Video

Updated: Sep 27, 2026

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

Danujan Sriranganathan1, Jonathan P Segal1, Mayur Garg2,3

  • 1Department of Gastroenterology, Hillingdon Hospitals NHS Foundation Trust, Uxbridge, UK.

Frontline Gastroenterology
|March 18, 2022
PubMed

Insights

The 2019 European Crohn's and Colitis Organisation guidelines detail biologic use for Crohn's disease remission induction, maintenance, and fistulising perianal disease treatment. This review highlights key recommendations for these therapeutic strategies.

Area of Science:

  • Gastroenterology
  • Immunology
  • Pharmacology

Background:

  • The European Crohn's and Colitis Organisation (ECCO) published updated guidelines in 2019 for managing Crohn's disease.
  • Crohn's disease management involves induction and maintenance of remission, alongside specific treatments for fistulising perianal disease.

Purpose of the Study:

  • To summarize the key recommendations from the 2019 ECCO guidelines.
  • To focus on the strategic use of biologic therapies in Crohn's disease management.
  • To provide an overview of biologic treatment for remission induction, maintenance, and fistulising perianal disease.

Main Methods:

  • Review of the 2019 ECCO guidelines on medical management of Crohn's disease.
  • Analysis of recommendations pertaining to biologic therapies.
  • Synthesis of information on induction, maintenance, and fistulising perianal disease treatment.

Main Results:

  • Key recommendations for biologic use in Crohn's disease are outlined.
  • Guidance covers induction of remission, maintenance of remission, and treatment of fistulising perianal disease.
  • The review emphasizes the role of biologics in various treatment settings.

Conclusions:

  • Biologic therapies are central to the management strategies recommended by ECCO for Crohn's disease.
  • The guidelines provide a framework for optimizing biologic use in different clinical scenarios.
  • Effective utilization of biologics is crucial for improving patient outcomes in Crohn's disease.

Keywords:
Crohn's disease

More Related Videos

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing07:38

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing

Published on: September 13, 2016

In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction08:02

In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction

Published on: January 22, 2020

Related Concept Videos

Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation. 
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the colonic...
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...